Warner (India) Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 17 Year, 7 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 19.13%
(FY 2023)
- Profit 10.66%
(FY 2023)
- Ebitda 103.38%
(FY 2023)
- Net Worth 53.58%
(FY 2023)
- Total Assets 42.98%
(FY 2023)
About Warner (India) Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mayank Goel, Ashutosh Goel, and Gyanesh Jeswal serve as directors at the Company.
- CIN/LLPIN
U85191DL2007PTC171397
- Company No.
171397
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Dec 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Warner (India) Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayank Goel  | Director | 28-Sep-2020 | Current |
| Ashutosh Goel | Director | 28-Sep-2020 | Current |
| Gyanesh Jeswal | Director | 13-Dec-2007 | Current |
Financial Performance and Corporate Structure Insights of Warner (India) Pharma.
Warner (India) Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.13% increase. The company also saw a substantial improvement in profitability, with a 10.66% increase in profit. The company's net worth Soared by an impressive increase of 53.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Warner (India) Pharma?
In 2023, Warner (India) Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Admed Overseas Private LimitedActive 17 years 7 daysMayank Goel and Gyanesh Jeswal are mutual person
- Palohma Healthcare Private LimitedActive 1 year 7 months
Mayank Goel and Ashutosh Goel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Warner (India) Pharma?
Unlock and access historical data on people associated with Warner (India) Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Warner (India) Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Warner (India) Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
